P-ERK1/2 and P-JNK inhibitors and agonists confirmed that the protective effects of AMBP against CAVD were mediated via these pathways in vivo and in vitro. This evidence concerns the gene MAPK3 and congenital bilateral aplasia of vas deferens from CFTR mutation.